Axcella Stock
Axcella is a biotechnology company providing therapeutics development solutions.
About Axcella Stock
Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products.
Funding History
| October 2013 | $10.8M |
|---|---|
| December 2013 | $0 |
| May 2015 | $39.0M |
| February 2016 | $42.5M |
| November 2018 | $59.0M |
Management
Founder
David Berry
Senior Vice President and Chief Medical Officer
Christopher Wright
CFO
Jeff Moore
President and Chief Executive Officer
William Hinshaw
President of R&D and Chief Scientific Officer
Peter Mueller
Co-Founder
Geoffrey von Maltzahn
Principal Research Fellow
Eugenio Ferrari
VP, Research
Michael Hamill
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Axcella or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
